top of page


Medicines that reach the source of immune-mediated diseases

We develop powerful and precisely-designed therapeutics that have the potential to transform the treatment of immune-mediated diseases — and improve the lives of people suffering from them.


Our lead asset is solrikitug, a highly potent monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), which was in-licensed from Merck & Co., Inc. (known as MSD outside of the U.S. and Canada). Solrikitug has the potential to be a life-changing medication for a significant group of patients who currently have minimal treatment options.



Phase I

Phase II

Phase III




Undisclosed GI Target

Given TSLP's position as the "master switch" cytokine sitting at the top of the inflammatory cascade, solrikitug could have potential utility in a wide array of immunology and inflammation programs. Our research suggests that the ceiling of efficacy for the TSLP class has not yet been reached in existing therapeutics, and we aim to deliver best-in-class efficacy across multiple respiratory and gastrointestinal (GI) indications through appropriate dose optimization.


Solrikitug is nearing Phase 2 clinical trials in chronic obstructive pulmonary disease (COPD) and asthma, and we have already established a robust manufacturing process to optimize development and enable rapid progression into late-stage development.

About COPD

Chronic obstructive pulmonary disease (COPD) is a common and long-term lung condition that often results in restricted or blocked airflow, chronic cough and breathing problems due to significant lung damage. COPD encompasses a group of diseases, including emphysema and chronic bronchitis, and is a progressive disease that gets worse over time. There are currently no biologics approved for COPD, which affects 400 million people worldwide and 16 million in the United States. It’s the third-leading cause of death around the world and a major cause of disability.


About Asthma

Asthma is a chronic disease that causes inflammation in the airways, making it harder to breathe. It’s estimated to affect more than 260 million people across the globe and over 27 million people in the United States, including 4.5 million children. While it ranges in severity, symptoms include breathlessness, chest tightness, wheezing and coughing. An estimated 5-10% of people with asthma in the U.S. have severe asthma, which means their asthma remains uncontrolled despite high medicine doses (typically inhaled corticosteroids along with a second controller medication). This patient population continues to have significant unmet needs despite the variety of therapeutics available for asthma.

We are actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no available treatments.
bottom of page